Academia
The Prostate Cancer Foundation has been an early accelerator of research that is now coming to fruition, including the early research into PSMA and the discovery that two FDA-approved PARP inhibitors, olaparib (Lynparza) and rucaparib (Rubraca) could work against mutant genes in prostate cancer.
The WHO’s Emergency Use Listing (EUL), a prerequisite for COVAX Facility vaccine supply, evaluates the safety, quality, and efficacy of the COVID-19 vaccines. As such, today’s approval allows the vaccine to be used by agencies and NGOs around the world.
Early results from University of Oxford’s RECOVERY trial showed Roche’s immunosuppressant Actemra reduced deaths and the need for mechanical ventilation in severe COVID patients.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for February 9, 2021.
A new study report in Science suggests SARS-CoV-2 and its mutated new variants can evade immune responses via the selective deletion of small sections of the virus’s genetic sequence.
Studies suggest the severity of COVID-19 infection may be lessened by flu vaccine.
Treatments for HIV are poised for another breakthrough. Researchers at Washington University in St. Louis (WUSTL) have discovered a way to eradicate dormant HIV virus within the cells, before it becomes active.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
On the other hand, when dealing with a novel coronavirus, a certain amount of speed and urgency is necessary. Professor Chris Molloy, Chief Executive Officer of the U.K,’s Medicines Discovery Catapult, told BioSpace that real-time data should be considered, with a different lens applied.
PRESS RELEASES